The Patent Finder

Combinatorial Cancer Immunotherapy (2021)

Senti Biosciences, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 11,419,898Combinatorial Cancer Immunotherapy
In force
 · High confidence
Senti Biosciences, Inc.In force
High confidence
US 10,993,967Combinatorial Cancer Immunotherapy
Lapsed May 4, 2025 on the fee record
High confidence
Senti Biosciences, Inc.Lapsed May 4, 2025 on the fee record
High confidence
Application 17/848,320Combinatorial Cancer Immunotherapy
Abandoned
Abandoned Aug 21, 2026
Senti Biosciences, Inc.AbandonedAbandoned Aug 21, 2026
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Senti Biosciences, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited